Valacyclovir interactions
Checked as Valaciclovir in this data source.
Full monograph for ValacyclovirCheck it against another medicine
Medicines
485 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Everolimusmatched approximately | Major | Synergy | Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive… | 4 sources — open the full entry |
| Iodixanolmatched approximately | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iohexolmatched approximately | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Iopamidolmatched approximately | Major | Synergy | Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal… | 7 sources — open the full entry |
| Tacrolimus MonohydrateOralTopicalmatched approximately | Major | Synergy | Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive… | 4 sources — open the full entry |
| Tenofovir Alafenamidematched approximately | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| Tenofovir Disoproxilmatched approximately | Major | Excretion | Coadministration of tenofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Additionally… | 8 sources — open the full entry |
| Adefovir Dipivoxilmatched approximately | Moderate | Excretion | Theoretically, coadministration of adefovir dipivoxil with other drugs that are eliminated by active tubular secretion may result in increased plasma… | 1 sources — open the full entry |
| Amikacinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Betamethasone + Neomycin Sulphate (Ophthalmic)matched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Carboplatinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Framycetin + Esculinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Cinchocaine + Hydrocortisone + Neomycin + Esculinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Cisplatinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Clobetasol Propionate + Neomycin Sulphate + Nystatinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…3 documented mechanisms | 2 sources — open the full entry |
| Cyclosporine (Oral)matched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acidmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphatematched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Dexamethasone + Tobramycinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Entecavir Monohydratematched approximately | Moderate | Excretion | Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or… | 2 sources — open the full entry |
| Fluocinolone Acetonide + Neomycin Sulfatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Fluormetholone + Neomycin Sulphatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Fluorometholone + Gentamicinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Gentamicin + Hydrocortisone Acetatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Gentamicin SulfateInjectionOphthalmicmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Gramacidin + Neomycin + Polymixin Bmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Hydrocortisone + Neomycin Sulphate + Polymixin Bmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Hydrocortisone Acetate + Neomycin Sulphatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Loteprednol Etabonate + Tobramycinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Mesalazine [5-aminosalicylic acid]matched approximately | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| Methotrexatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Metronidazole + Neomycin Sulphate + Polymyxin B + Nystatinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…3 documented mechanisms | 2 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zincmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Neomycin Sulfate + Bacitracin Zinc + Polymyxin B Sulfatematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Neomycin Sulphate + Polymyxin B Sulphate + Pramoxinematched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Oxaliplatinmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Pemetrexedmatched approximately | Moderate | Excretion | Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive… | 1 sources — open the full entry |
| Pethidine Hydrochloridematched approximately | Moderate | Others | Acyclovir may increase the plasma concentrations of meperidine and normeperidine, the metabolite that has been associated with adverse effects such as… | 2 sources — open the full entry |
| Prednisolone + Neomycin Sulphate + Polymixin B Sulphatematched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…2 documented mechanisms | 2 sources — open the full entry |
| Remdesivirmatched approximately | Moderate | Excretion | Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient… | 5 sources — open the full entry |
| Sulfasalazinematched approximately | Moderate | Synergy | Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the… | 4 sources — open the full entry |
| TobramycinNebuliser SolutionOphthalmicmatched approximately | Moderate | Synergy | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or… | 2 sources — open the full entry |
| Triamcinolone + Neomycin + Nystatin + Gramicidinmatched approximately | Moderate | Synergy · Unknown | The concurrent use of valaciclovir with other nephrotoxic drugs may increase the risk of renal toxicity. Patients who are elderly, debilitated, dehydrated, or…3 documented mechanisms | 2 sources — open the full entry |
| Trospium Chloridematched approximately | Moderate | Excretion | Theoretically, coadministration of trospium chloride with other drugs that are eliminated by active tubular secretion may result in increased plasma… | 4 sources — open the full entry |
| Lamivudine + Zidovudinematched approximately | Minor | Others · Unknown | Excessive lethargy has been reported in patients receiving concomitant acyclovir and zidovudine. This interaction has not been reported with valacyclovir, but…2 documented mechanisms | 6 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapinematched approximately | Minor | Others · Unknown | Excessive lethargy has been reported in patients receiving concomitant acyclovir and zidovudine. This interaction has not been reported with valacyclovir, but…3 documented mechanisms | 6 sources — open the full entry |
| Memantine + Donepezilmatched approximately | Minor | Excretion · Unknown | Theoretically, the concomitant administration of memantine and other drugs that undergo active renal tubular secretion may result in altered plasma levels of…2 documented mechanisms | 5 sources — open the full entry |
| Memantine Hydrochloridematched approximately | Minor | Excretion | Theoretically, the concomitant administration of memantine and other drugs that undergo active renal tubular secretion may result in altered plasma levels of… | 5 sources — open the full entry |
| Mycophenolate Mofetilmatched approximately | Minor | Excretion | Coadministration with mycophenolic acid may increase the plasma concentrations of acyclovir. The mechanism of interaction has not been described. However… | 4 sources — open the full entry |
Conditions
Conditions in which Valacyclovir needs care, as documented in this source.
Dehydration
ModerateValacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney. Cases of acute renal failure have been reported in patients without adequate hydration. Acyclovir may precipitate in renal tubules when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients. If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored.
1 source
- "Product Information. Valtrex (valacyclovir)." Glaxo Wellcome (2001):
Diseases requiring hemodialysis
ModerateValacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism. About one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session. The recommended dose of valacyclovir should be administered after hemodialysis.
1 source
- "Product Information. Valtrex (valacyclovir)." Glaxo Wellcome (2001):
Kidney Diseases
ModerateValacyclovir is almost completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism; acyclovir is primarily eliminated by the kidney. Cases of acute renal failure and CNS side effects (including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in patients with preexisting renal disease who received higher-than-recommended doses of valacyclovir for their level of renal function. Cases of acute renal failure have also been reported in patients receiving other nephrotoxic agents. Therapy with valacyclovir should be administered cautiously in elderly patients (with or without renal dysfunction) and patients receiving other nephrotoxic agents. Dosage reductions are recommended in patients with renal dysfunction. If acute renal failure and anuria occur, patients may benefit from hemodialysis until renal function is restored; valacyclovir should be discontinued if CNS side effects develop.
1 source
- "Product Information. Valtrex (valacyclovir)." Glaxo Wellcome (2001):
Purpura, Thrombotic Thrombocytopenic
ModerateThrombotic thrombocytopenic purpura/hemolytic uremia syndrome (TTP/HUS), in some cases resulting in death, has been reported in patients with advanced HIV-1 disease, in allogeneic bone marrow transplant recipients, and in renal transplant recipients during clinical trials of valacyclovir at doses of 8 g/day. Therapy with valacyclovir should be discontinued immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS develop.
1 source
- "Product Information. Valtrex (valacyclovir)." Glaxo Wellcome (2001):